An Open Trial to Assess the Tolerability of AVANZ® Salsola Immunotherapy

Inclusion Criteria: * A clinical history of Salsola kali pollen induced allergic rhinoconjunctivitis with or without asthma at least one year prior to trial entry. * Positive Skin Prick Test to Salsola kali pollen (wheal diameter ≥ 3 mm). * Documenting in the last 5 years a positive specific Immunoglobulin E against Salsola kali pollen (≥ Class 2; ≥0.70 KU/L). Exclusion Criteria: * Forced expiratory volume at one second 1 \< 70% of predicted value at screening after adequate pharmacologic treatment. * Uncontrolled or severe asthma. * History of severe asthma exacerbation or emergency room visit or admission for asthma in the previous 12 months. * At screening, current symptoms of, or treatment for, upper respiratory tract infection, acute sinusitis, acute otitis media or other relevant infection (serous otitis media is not an exclusion criterion). * Treatment with parenteral corticosteroids, oral corticosteroids or anti-IgE in the previous 3 months or during the study (except for steroids if needed as rescue medication). * Currently treated with angiotensin converting enzyme (ACE) inhibitors, tricyclic antidepressants, β-blockers, mono amine oxidase inhibitors (MAOIs) and any other drug containing alum (e.g. antacids) taken on a daily basis. * Immunotherapy with Cupressus arizonica or Salsola kali pollen extracts within the previous 5 years (initiation of subcutaneous immunotherapy is acceptable if treatment has been discontinued before reaching maintenance dose; for SLIT 3 months in the last 5 years is accepted) or concomitant immunotherapy with any other allergen. * History of anaphylactic shock due to e.g. food, insect venom, exercise or drug. * History of severe and recurrent angioedema.